Chromosomal rearrangements (translocations, inversions, deletions or insertions) of independent (isolated) genes result in chimeric genes or gene fusions and have been implicated in many types of cancers (solid tumors and hematological malignancies). Originally identified in the 1980s, these fusion genes have been identified as playing a major role in precision/personal medicine and are used as therapeutic biomarkers for diagnosis, prognosis, and drug development. Since fusion genes are used for diagnostic and prognostic purposes and are targets for treatment, assessing their function in cancer is critical. However, the functional role of these mutations is unclear. Most studies that elucidate the mechanisms of cancer mutations rely on gene knockout/function loss or insertion and overexpression of recombinant genes. However, these cell line models do not reflect the clinical situation of chromosomal translocations.
CRISPR/Cas9 platformCB, one of the leading genetic editing services companies, is specializing in building efficient systems and procedures to meet the needs and timelines of clients working in the CRISPR/Cas9 gene editing. To systematically study the role of fusion genes in tumor cells, we can customize the chromosomal rearrangements (translocation/ reverse/missing/inserting) required for engineering in your chosen cell line.
